IFN β-1b group N = 303 | Other DMTs group N = 21 | Total N = 324 | |
---|---|---|---|
Age (years) | |||
Mean | 41.5 ± 11.29 | 44.9 ± 11.15 | 41.8 ± 11.30 |
Median (min–max) | 40.0 (19.0–68.0) | 43.0 (24.0–68.0) | 40.0 (19.0–68.0) |
Women, n (%) | 207 (68.3) | 14 (66.7) | 221 (68.2) |
Subtype of MS, n (%) | |||
CIS | 7 (2.3) | 0 (0.0) | 7 (2.2) |
RRMS | 286 (94.4) | 19 (90.5) | 305 (94.1) |
SPMS | 10 (3.3) | 2 (9.5) | 12 (3.7) |
MS disease history | |||
Duration since MS diagnosis (years) | |||
Mean | 6.7 ± 6.36 | 9.5 ± 9.16 | 6.9 ± 6.59 |
Median (min–max) | 4.6 (0.2–35.0) | 7.5 (0.3–43.4) | 4.8 (0.2–43.4) |
Presence of exacerbations, n (%) | 120 (39.6) | 13 (61.9) | 133 (41.0) |
Number of exacerbations | |||
Mean | 1.5 ± 0.74 | 1.9 ± 1.14 | 1.6 ± 0.79 |
Median (min–max) | 1.0 (0.0–5.0) | 2.0 (1.0–5.0) | 1.0 (0.0–5.0) |
Reasons for switching to ExtaviPro™, n (%) | |||
Clinical reasonsa | |||
Availability of new auto-injector (patient already treated with Extavia®) | 296 (97.7) | 2 (9.5) | 298 (92.0) |
Lack/loss of effectiveness of current treatment, as evidenced by | |||
returning/worsening/progressing MS symptoms | 2 (0.7) | 6 (28.6) | 8 (2.5) |
Increasing frequency of relapses/symptomatic phases | 2 (0.7) | 3 (14.3) | 5 (1.5) |
MRI evaluation | 3 (1.0) | 6 (28.6) | 9 (2.8) |
Other | 5 (1.7) | 1 (4.8) | 6 (1.9) |
Poor tolerance | 9 (3.0) | 7 (33.3) | 16 (4.9) |
Patient-centred reasons | |||
Compliance problem | 19 (6.3) | 9 (42.9) | 28 (8.6) |
Patient unable to consistently store current therapy under special conditions | 5 (1.7) | 2 (9.5) | 7 (2.2) |